Researcher Profile

Researcher Profile

Lisa McGregor, MD, PhD

Lisa McGregor, MD, PhD

Howard O. Jr. and Jean S. Beaver Professor of Pediatric Hematology/Oncology, Department of Pediatrics
Chief, Division of Hematology and Oncology
Scientific Program:Experimental Therapeutics
Disease Teams:
Pediatric Cancer
lmm56@psu.edu

Research Interests

  • Neoplasms
  • Neuroblastoma
  • Pediatrics
  • irinotecan
  • Therapeutics
  • Radiotherapy
  • Survival
  • Pharmacokinetics
  • oxaliplatin
  • Wilms Tumor
  • Maximum Tolerated Dose
  • Research

Clinical Trials

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1-21 years
Umbrella Long-term Follow-up Protocol
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Neuroblastoma Biology Studies
Renal Tumor Classification, Biology, and Banking Study
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors
Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
A Phase I/II, Multicenter, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Recent Publications

2015

Lam, CG, Furman, WL, Wang, C, Spunt, SL, Wu, J, Ivy, P, Santana, VM & McGregor, L 2015, 'Phase i clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors', Journal of Pediatric Hematology/Oncology, vol. 37, no. 1, pp. e13-e18. https://doi.org/10.1097/MPH.0000000000000186
Federico, SM, Allewelt, HB, Spunt, SL, Hudson, MM, Wu, J, Billups, CA, Jenkins, J, Santana, VM, Furman, WL & McGregor, L 2015, 'Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma', Journal of Pediatric Hematology/Oncology, vol. 37, no. 1, pp. e6-e12. https://doi.org/10.1097/MPH.0000000000000148

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)